Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zafar I Malik

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Journal of Ayub Medical College, Abbottabad : JAMC|August 12, 2005
Isolated appendicular tuberculosisS H Waqar, Zafar I Malik, M A Zahid
International Journal of Radiation Oncology, Biology, Physics|March 8, 2011
Impact of schedule duration on head and neck radiotherapy: accelerated tumor repopulation versus compensatory mucosal proliferationJohn D Fenwick, Juan Pardo-Montero, Alan E Nahum, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 10, 2010
Influence of dose calculation algorithms on isotoxic dose-escalation of non-small cell lung cancer radiotherapyVanessa Panettieri, Zafar I Malik, Chinnamani V Eswar, et al.
Plos Medicine|June 7, 2022
Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trialChris C Parker, Nicholas D James, Christopher D Brawley, et al.
The New England Journal of Medicine|June 6, 2017
Abiraterone for Prostate Cancer Not Previously Treated with Hormone TherapyNicholas D James, Johann S de Bono, Melissa R Spears, et al.
Lancet (London, England)|October 26, 2018
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trialChristopher C Parker, Nicholas D James, Christopher D Brawley, et al.
JNCI Cancer Spectrum|July 25, 2022
Docetaxel for Nonmetastatic Prostate Cancer: Long-Term Survival Outcomes in the STAMPEDE Randomized Controlled TrialNicholas D James, Fiona C Ingleby, Noel W Clarke, et al.
International Journal of Cancer|April 12, 2022
Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476)Nicholas D James, Noel W Clarke, Adrian Cook, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Journal of Ayub Medical College, Abbottabad : JAMC|August 12, 2005
Isolated appendicular tuberculosisS H Waqar, Zafar I Malik, M A Zahid
International Journal of Radiation Oncology, Biology, Physics|March 8, 2011
Impact of schedule duration on head and neck radiotherapy: accelerated tumor repopulation versus compensatory mucosal proliferationJohn D Fenwick, Juan Pardo-Montero, Alan E Nahum, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 10, 2010
Influence of dose calculation algorithms on isotoxic dose-escalation of non-small cell lung cancer radiotherapyVanessa Panettieri, Zafar I Malik, Chinnamani V Eswar, et al.
Plos Medicine|June 7, 2022
Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trialChris C Parker, Nicholas D James, Christopher D Brawley, et al.
The New England Journal of Medicine|June 6, 2017
Abiraterone for Prostate Cancer Not Previously Treated with Hormone TherapyNicholas D James, Johann S de Bono, Melissa R Spears, et al.
Lancet (London, England)|October 26, 2018
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trialChristopher C Parker, Nicholas D James, Christopher D Brawley, et al.
JNCI Cancer Spectrum|July 25, 2022
Docetaxel for Nonmetastatic Prostate Cancer: Long-Term Survival Outcomes in the STAMPEDE Randomized Controlled TrialNicholas D James, Fiona C Ingleby, Noel W Clarke, et al.
International Journal of Cancer|April 12, 2022
Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476)Nicholas D James, Noel W Clarke, Adrian Cook, et al.
Pageof 1